The Hetero Ring Contains At Least Three Nitrogens Patents (Class 540/474)
  • Patent number: 10195295
    Abstract: A process for purifying a compound of formula 1, includes the following steps: a) adding an acid to an aqueous solution of the compound of formula 1, including salts and hydrates thereof so as to obtain a slurry having a pH?3; and b) filtering the slurry and at least one time washing the obtained precipitate with a liquid comprising water; and c) dissolving the precipitate obtained in step b) in water to obtain an aqueous solution; and d) filtering of the solution obtained in step c) over a nanofiltration membrane having a Molecular Weight Cut Off in the range from 150 to 500 and wherein optionally, between step c) and step d) the pH of the aqueous solution is adjusted to a pH value in the pH range as specified by the manufacturer of the nanofiltration membrane. A process for preparing a gadolinium complex of the purified compound of formula 1 is also disclosed. This gadolinium complex can be used for making a pharmaceutical composition as a contrast agent for magnetic resonance imaging.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: February 5, 2019
    Assignee: T2PHARMA GMBH
    Inventors: Diederik Buffel, Xavier Boi, Judith Pype
  • Patent number: 10072027
    Abstract: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: September 11, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 9920082
    Abstract: The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: March 20, 2018
    Assignee: CISBO BIOASSAYS
    Inventors: Laurent Lamarque, David Parker, Stephen J. Butler, Martina Delbianco
  • Patent number: 9890297
    Abstract: The present invention relates to an oxidatively curable coating formulation comprising an oxidatively curable alkyd-based resin and a bis-triazacyclononane-based chelant, which chelant may optionally be complexed with a suitable transition metal ion, particularly manganese. The formulations may be paints or other oxidatively curable coating compositions. The invention also provides methods for making such formulations and compositions resultant from the curing of such formulations.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: February 13, 2018
    Assignee: Chemsenti Limited
    Inventors: Johannes Wietse De Boer, Ronald Hage, Karin Maaijen
  • Patent number: 9724436
    Abstract: The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 8, 2017
    Assignee: BAYER AS
    Inventor: Thomas Ramdahl
  • Patent number: 9393329
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: July 19, 2016
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Patent number: 9315510
    Abstract: Biologically active compounds are provided that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: April 19, 2016
    Assignee: Biolitec Pharma Marketing LTD
    Inventors: Arno Wiehe, Daniel Aicher, Christian B. W. Stark, Volker Albrecht, Susanna Gräfe
  • Patent number: 9115094
    Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N?,N?,N??-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: August 25, 2015
    Assignee: THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS)
    Inventor: Hyun-soon Chong
  • Patent number: 9062009
    Abstract: The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 23, 2015
    Assignee: National Yang Ming University
    Inventors: Cheng Allen Chang, Ren-Shyan Liu, Bhalchandra Vishnu Bhagwat
  • Publication number: 20150148524
    Abstract: A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of: (i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II): (Formulae (I), (II)) wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and each X is independently selected from H and an effector molecule; in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and (ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse s
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Zhen Wang, Andrea Robinson, Nicolas Daniel Spiccia, William Roy Jackson
  • Publication number: 20150133645
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 14, 2015
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Publication number: 20150125388
    Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.
    Type: Application
    Filed: May 27, 2013
    Publication date: May 7, 2015
    Applicant: Vniversity of Massachusetts Medical School
    Inventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
  • Publication number: 20150119553
    Abstract: Compounds are disclosed that are useful for noninvasive imaging in the near-infrared spectral range.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 30, 2015
    Inventors: Xinshe Xu, Daniel R. Draney, Lael Cheung
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Publication number: 20150094465
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Application
    Filed: September 2, 2014
    Publication date: April 2, 2015
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20150078998
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: Pharmaceutical compositions may include a complex of a radionuclide and a compound of Formula I or Formula II.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Applicant: MOLECULAR INSIGHT PHARMACEUTICALS
    Inventors: John W. BABICH, Craig ZIMMERMAN, John L. JOYAL, Genliang LU
  • Publication number: 20150071863
    Abstract: The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 12, 2015
    Inventor: Marc Anton WALTERS
  • Patent number: 8975395
    Abstract: The present invention relates to a material notably adapted for the extraction of metal cations in an aqueous medium, comprising a solid support on which are attached polyazacycloalkane compounds having a ring including at least 4 nitrogen atoms, and wherein the nitrogen atoms of the ring are substituted with coordinating groups, which each are independently: a coordinating group of formula: —(CH2)n—C(?O)—NR1R2 ?or else a both coordinating and binding group, fitting the formula: —(CH2)p—C(?O)—NR3-(A)-[support]. The invention also relates to methods for preparing the aforementioned materials and to different uses thereof, notably for the extraction of Pb2+ cations in an aqueous medium.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: March 10, 2015
    Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Michel Meyer, Arnaud Bucaille, Francois Cuenot, Franck Denat, Frédéric Boschetti, Roger Guilard
  • Patent number: 8951499
    Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: February 10, 2015
    Assignees: University of Washington, Glycorex Transplantation AB
    Inventors: D. Scott Wilbur, Bengt E. B. Sandberg
  • Publication number: 20140363376
    Abstract: In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Xiankai SUN, Amit Kumar, Zoltan Kovacs
  • Patent number: 8907082
    Abstract: The present invention provides improved processes for the synthesis of 1,4-ditosyl-1,4,7-triazacyclonone, comprising deprotecting a compound of formula (C): wherein P is tosylate or arylsulfonate, with an acidic medium to form 1,2-bis(1,4,7-triazacyclonon-1-yl)-ethane; and subsequently adding formaldehyde and formic acid to the acidic medium to form 1,2-bis-(4,7-dimethyl-1,4,7-triazacyclonon-1-yl)-ethane (Me4-DTNE). The syntheses of intermediates are also disclosed.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: December 9, 2014
    Assignee: Catexel Limited
    Inventors: Ronald Hage, Jean Hypolites Koek, Stephen William Russell, Lodewijk Van der Wolf, Jianrong Zhang, Wei Zhao, Xiaohong Wang
  • Patent number: 8901294
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: December 2, 2014
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Tae-Jeong Kim, Yong Min Chang, Hee-Kyung Kim, Sung-Wook Gu
  • Patent number: 8900780
    Abstract: Disclosed are a photosensitive resin composition for a color filter and a color filter using the same. The photosensitive resin composition for a color filter includes (A) a dye represented by the following Chemical Formula 1, (B) an alkali soluble resin, (C) a photopolymerizable monomer, (D) a photopolymerization initiator, and (E) a solvent.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 2, 2014
    Assignee: Cheil Industries Inc.
    Inventors: Jae-Hyun Kim, Kyung-Soo Moon, Myoung-Youp Shin, Dong-Hoon Won, Seung-Hyun Kim, Atsushi Endo, Hwan-Sung Cheon, Gyu-Seok Han
  • Publication number: 20140336373
    Abstract: The present invention concerns complexing agents of formula (I) in which a, b, c, chrom1, chrom2, chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesizing said agents.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 13, 2014
    Applicants: CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE LYON
    Inventors: Laurent Lamarque, Olivier Maury, David Parker, Jurriaan Zwier, James W. Walton, Adrien Bourdolle
  • Patent number: 8877157
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: November 4, 2014
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20140323717
    Abstract: Special C-functionalized cyclic bisaminal compounds having formula (I) or (II), their salts or solvates, methods for their preparation, their uses, and methods for preparing functional tetraazacycloalkane compounds implementing such cyclic bisaminal compounds.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Inventors: Raphael Tripier, Nathalie Camus
  • Publication number: 20140323719
    Abstract: The present invention relates to an improved process for the purification of polyaminocarboxylates such as DOTA, DTPA, DO3A-butrol, BOPTA.
    Type: Application
    Filed: November 26, 2012
    Publication date: October 30, 2014
    Inventors: Jagadeesh Babu Rangisetty, Manik Reddy Pullaguria, Rajesh Bhudeti
  • Patent number: 8865890
    Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: October 21, 2014
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Milko E. Van Der Boom, Atindra D. Shukla, David Rosenblatt, Tarkeshwar Guptar
  • Patent number: 8859492
    Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.
    Type: Grant
    Filed: May 12, 2012
    Date of Patent: October 14, 2014
    Assignee: MetalloPharm, LLC
    Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
  • Patent number: 8852553
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 7, 2014
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20140295213
    Abstract: The invention relates to a method for functionalizing an electrically conductive substrate, which is not a substrate made of gold, via a layer of chemical compounds, said method comprising the following steps: a step in which the electrically conductive substrate is placed in contact with chemical compounds comprising at least a disulfide terminal group; a step in which the disulfide terminal group of said chemical compounds is electro-oxidized, causing said chemical compounds to form a layer at the surface of the electrically conductive substrate.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 2, 2014
    Applicants: UNIVERSITE JOSEPH FOURIER, Commissariat a l'energie atomique et aux ene alt
    Inventors: Eric Jalaguier, Julien Buckley, Xavier Chevalier, Guy Royal
  • Publication number: 20140286927
    Abstract: A engineered composition and method of delivery of said composition providing effective therapy for the treatment of ulcerative colitis, and Crohn's disease.
    Type: Application
    Filed: June 19, 2012
    Publication date: September 25, 2014
    Inventor: Peter Edward Smith
  • Publication number: 20140271465
    Abstract: The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Mallinckrodt LLC
    Inventors: John N. Freskos, Mary Dyszlewski, Lori Chinen, Hector Knight, Michelle Schmidt
  • Publication number: 20140255306
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
    Type: Application
    Filed: January 10, 2014
    Publication date: September 11, 2014
    Applicant: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. BABICH, Craig ZIMMERMAN, John L. JOYAL, Genliang LU
  • Patent number: 8828565
    Abstract: Disclosed is a lubricant composition comprising at least one kind of compound represented by following formula (1): where X represents a cyclic group that may be substituted; Y represents a divalent or higher-valent linking group having at least one polar group and having no aromatic cyclic group; p1 represents an integer of 1 to 4; p2, p3, and p4 each represent an integer of 0 to 4; q represents an integer of 0 to 30; n represents an integer of 1 to 10; s represents an integer of 1 to 4; and t represents an integer of 2 to 10.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 9, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Hiroki Sugiura, Masayuki Harada, Ken Kawata, Akiko Hattori, Atsushi Tatsugawa
  • Publication number: 20140243397
    Abstract: The present invention generally relates to carriers including polymers and lipids that comprise a CXCR4 inhibiting moiety. More specifically, these carriers are biodegradable and can be bioreducible polymers that comprise a CXCR4 inhibiting moiety. These carriers can be suitable for delivery of nucleic acids to cells. These carriers and pharmaceutical compositions can be used to treat various conditions including cancers and inflammation conditions.
    Type: Application
    Filed: October 15, 2012
    Publication date: August 28, 2014
    Inventors: David Oupicky, Jing Li
  • Publication number: 20140241985
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Application
    Filed: June 13, 2012
    Publication date: August 28, 2014
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Publication number: 20140206862
    Abstract: Amine chelates capable of antioxidant capacity and amyloid disaggregation are shown which may be useful in targeting metal-based oxidative stress in neurodegenerative disorders. Pyclen, a backbone commonly investigated for contrast agent imaging, may be repurposed as an anti-oxidant chelator for disaggregating amyloid. The antioxidant capacity of pyclen is enhanced dramatically via conversion of the pyridine backbone to a pyridol with cellular studies showing superior antioxidant capacity while retaining chelation ability to protect amyloid from metal ions aggregation and also disaggregate amyloid aggregates. Another family of molecules based upon hybrid heterocyclic amine ligands is also presented.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 24, 2014
    Applicant: Texas Christian University
    Inventors: Kayla Nalynn Green, Kimberly Marie Lincoln, Paulina Gonzalez
  • Patent number: 8778919
    Abstract: The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N; —X1— represents C1-4alkyl, in particular methyl; —X2— represents —C1-4alkyl- or —C1-4alkyl-NR7—, in particular propyl, -ethyl-NR7— or -propyl-NR7—; —Y— represents —NR2—C1-6alkyl-CO—NR4—, -Het1-C1-6alkyl-CO—NR5— or -Het2-CO—NR6— and wherein the —C1-6alkyl-linker of —NR2—C1-6alkyl-CO—NR4— or -Het1-C1-6alkyl-CO—NR5— is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl; R1 represents hydrogen, chloro, fluoro or bromo; R2 represents —C1-4alkyl-, in particular ethyl or methyl; R7 represents hydrogen; R8 represents hydrogen; R4, R5 and R6 represent hydrogen; Het1 is selected from piperazinyl or piperidinyl, in particular -piperazinyl; Het2 selected from pyrrolidinyl or piperidinyl, in particular pyrrolid
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: July 15, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frederik Jan Rita Rombouts, Christopher John Love, Kristof Van Emelen, Sven Franciscus Anna Van Brandt, Tongfei Wu
  • Publication number: 20140187527
    Abstract: The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics.
    Type: Application
    Filed: December 31, 2012
    Publication date: July 3, 2014
    Applicant: NATIONAL YANG MING UNIVERSITY
    Inventors: Cheng Allen Chang, Ren-Shyan Liu, Bhalchandra Vishnu Bhagwat
  • Publication number: 20140179015
    Abstract: The invention provides a compound of formula (I): (wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group); or (wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group).
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Applicant: University of Durham
    Inventors: David PARKER, Robert Pal
  • Publication number: 20140170066
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicants: Merck & Co., Inc., Visen Medical, Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Publication number: 20140142298
    Abstract: The present invention embodiments relate to a compound with formula (V?) The invention also relates in certain embodiments to the synthesis method for compound (V?) and its use for the preparation of 1,4,7-triazacyclononane (tacn) and N- and/or C-functionalized derivatives thereof, particularly compounds with formula (I) The invention also relates in certain embodiments to metallic complexes comprising a ligand with formula (I) and a metal and their use for imaging.
    Type: Application
    Filed: November 13, 2013
    Publication date: May 22, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BOURGOGNE
    Inventors: Franck Denat, Pauline Desogere, Claire Bernhard, Yoann Rousselin, Frederic Boschetti
  • Patent number: 8722879
    Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: May 13, 2014
    Assignee: Yeda Research & Development Company Ltd. at the Weizmann Institute of Science
    Inventors: Milko E. Van Der Boom, Atindra D. Shukla, David Rosenblatt, Tarkeshwar Gupta
  • Patent number: 8703937
    Abstract: Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: April 22, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Dennis A. Moore
  • Publication number: 20140073631
    Abstract: Disclosed are guanidine and biguanidine derivatives which have anti-viral and antibacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds. Methods of treating infections using the guanidine and biguanidine derivatives are also disclosed.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 13, 2014
    Applicant: Vymed Corporation
    Inventor: B. Vithal SHETTY
  • Publication number: 20140057877
    Abstract: This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
    Type: Application
    Filed: October 18, 2011
    Publication date: February 27, 2014
    Inventors: Michael A. Murphy, Mitchell R. Malachowski
  • Patent number: 8637620
    Abstract: The invention relates to a process for preparing a polymeric material doped with metal elements, comprising a step of polymerization of at least one monomer comprising at least one ethylenic function, said monomer being complexed with a metal element. Use of the materials obtained by means of this process as catalysts, or luminescent or magnetic materials, or as elements for laser targets.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: January 28, 2014
    Assignee: Commissariat A l'Energie Atomique et aux Energies Alternatives
    Inventors: Alexia Balland Longeau, Louis Moreau, Jérôme Thibonnet, Emilie Velasquez
  • Patent number: 8628978
    Abstract: A compound of formula (I) is provided: wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group; or wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 14, 2014
    Assignee: University of Durham
    Inventors: David Parker, Robert Pal
  • Publication number: 20130336888
    Abstract: A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.
    Type: Application
    Filed: December 6, 2011
    Publication date: December 19, 2013
    Inventors: John W. Babich, John L. Joyal, Craig Zimmerman